This change reflects the company's planned separation into two independent, publicly traded companies, NCR Voyix, focused on digital commerce, and NCR Atleos, focused on ATMs. The company's stock will begin trading on the New York Stock Exchange under the new ticker symbol "VYX" on October 17, 2023.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2023 | Buy → Neutral | Northcoast | |
| 9/19/2022 | $38.00 → $27.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/19/2021 | $55.00 | Overweight | Stephens & Co. |
| 8/4/2021 | $62.00 → $61.00 | Overweight | Morgan Stanley |
Northcoast downgraded NCR Corp from Buy to Neutral
Morgan Stanley downgraded NCR Corp from Overweight to Equal-Weight and set a new price target of $27.00 from $38.00 previously
Stephens & Co. initiated coverage of NCR with a rating of Overweight and set a new price target of $55.00
4 - NCR VOYIX Corp (0000070866) (Issuer)
4 - NCR VOYIX Corp (0000070866) (Issuer)
3 - NCR VOYIX Corp (0000070866) (Issuer)
NCR Corporation (NYSE:NCR), a leading enterprise technology provider, today announced a change of its name to NCR Voyix Corporation. This change reflects the company's planned separation into two independent, publicly traded companies, NCR Voyix, focused on digital commerce, and NCR Atleos, focused on ATMs. The separation is expected to be completed on October 16, 2023, at the close of business. The name change became effective on October 13, 2023. The company's stock will begin trading on the New York Stock Exchange under the new ticker symbol "VYX" on October 17, 2023. About NCR Corporation NCR Corporation (NYSE:NCR) is a leader in transforming, connecting and running technology pla
NEW YORK, Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE:NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. S&P MidCap 400 constituent NCR Corp. (NYSE:NCR) is spinning off NCR Atleos in a transaction expected to be completed on October 17. Following the spin-off, the NCR parent will have a name and symbol change to NCR Voyix Corp. (NYSE:VYX) and will remain in the S&P MidCap 400. iTeos Therapeutics is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Nam
NCR Atleos and NCR Voyix on track to become independent companies after close of business on October 16, 2023 NCR Corporation (NYSE:NCR), a leading enterprise technology provider, today announced the members of the boards of directors for NCR Atleos ("Atleos") and NCR Voyix ("Voyix") following the planned separation. This marks one of the final steps in the process to separate into two independent, publicly traded companies. Assuming completion of the separation, effective October 17, 2023, the new corporations will initiate trading under stock symbols, (NYSE:NATL) for Atleos and (NYSE:VYX) for Voyix. NCR Atleos The board of directors for Atleos will be comprised of executives across th
Atleos common stock will begin trading "regular way" on the New York Stock Exchange under the ticker symbol "NATL" at market open on October 17, 2023.
This change reflects the company's planned separation into two independent, publicly traded companies, NCR Voyix, focused on digital commerce, and NCR Atleos, focused on ATMs. The company's stock will begin trading on the New York Stock Exchange under the new ticker symbol "VYX" on October 17, 2023.
NCR Corporation (NYSE:NCR) shares are trading higher on Wednesday following reports suggesting the company is in talks to merge its ATM business with Brink's Co. (NYSE:BCO). What To Know: Despite the news of the reports, Brink's later released a statement denying the speculation. Despite this, shares still were up over 3%. Also on Wednesday, the company announced that Michael D. Hayford is retiring as CEO following the successful separation of NCR into NCR Atleos and NCR Voyix, which is expected to happen on Oct. 16. According to data from Benzinga Pro, the stock experienced above-average trading volume of 7.76 million shares compared to its average volume of 1.10 million. Related Link:
NEW YORK, Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE:NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. S&P MidCap 400 constituent NCR Corp. (NYSE:NCR) is spinning off NCR Atleos in a transaction expected to be completed on October 17. Following the spin-off, the NCR parent will have a name and symbol change to NCR Voyix Corp. (NYSE:VYX) and will remain in the S&P MidCap 400. iTeos Therapeutics is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Nam
ATLANTA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cumulus Media Inc. (NASDAQ:CMLS) today announced that Deborah Farrington, Co-Founder and Managing Partner of StarVest Partners, LP, has been appointed to the Cumulus Media Board of Directors. "Deborah is a highly respected and accomplished venture capital pioneer and experienced board member of Fortune 500 and leading public technology companies," said Mary G. Berner, President and Chief Executive Officer of Cumulus Media. "As such, Deborah brings valuable strategic insights that will support the execution of our audio-first strategy and nicely complement our existing Board expertise. We are confident that Deborah's proven business acumen will be
CHICAGO, Sept. 24, 2021 /PRNewswire/ -- JBT Corporation (NYSE:JBT), a global technology solutions provider to high-value segments of the food and beverage industry, announced today the promotion of Robert "Bob" Petrie effective October 7th to the position of Executive Vice President and President, Protein. He succeeds Paul Sternlieb, who provided notice of his resignation from JBT in connection with his acceptance of the Chief Executive Officer position at an industrial public company, that is not competitive to JBT. Since 2016, Bob has led JBT's Protein EMEA (Europe, Middle East, and Africa) business, and at the start of this year assumed additional responsibility for JBT's Protein business
4 - NCR VOYIX Corp (0000070866) (Issuer)
4 - NCR VOYIX Corp (0000070866) (Issuer)
SC 13G/A - NCR VOYIX Corp (0000070866) (Subject)
SC 13G/A - NCR CORP (0000070866) (Subject)
SC 13G/A - NCR CORP (0000070866) (Subject)
S-8 - NCR VOYIX Corp (0000070866) (Filer)
8-K - NCR VOYIX Corp (0000070866) (Filer)
144 - NCR VOYIX Corp (0000070866) (Subject)
Strong First Half Pushes Expectations to Higher End of Previous Guided Ranges NCR Corporation (NYSE:NCR) reported financial results today for the three months ended June 30, 2023. Second quarter results and other recent highlights include: Revenue of $2.0 billion; Recurring revenue of $1.3 billion Net income from continuing operations attributable to NCR of $20 million Adjusted EBITDA of $389 million GAAP diluted EPS from continuing operations of $0.11; Non-GAAP diluted EPS of $0.94 Net cash provided by operating activities of $227 million; Adjusted free cash flow-unrestricted of $154 million Company progressing toward separation into two public companies "We delivere
NCR Corporation (NYSE:NCR) will release its second quarter 2023 financial results after the market close on Wednesday, August 2, 2023. A conference call is scheduled at 4:30 p.m. Eastern Time on the same day. Participants should plan to access the call 15 minutes prior to the start time to ensure a smooth connection. Details are as follows: Dial in Number Passcode Time/Date Conference call 888-820-9413 (Tollfree) +1 786-460-7169 (Local) 9356480 4:30 p.m. Eastern, Aug. 2, 2023 The live conference call and related presentation materials will also be available at http://investor.
Separation Into Two Leading Public Companies On Track NCR Corporation (NYSE:NCR) reported financial results today for the three months ended March 31, 2023. First quarter results and other recent highlights include: Revenue of $1.9 billion, up 1%; up 4% on a constant currency basis Recurring revenue of $1.2 billion, up 4% and up 7% on a constant currency basis Net income from continuing operations attributable to NCR of $9 million, up 127% Adjusted EBITDA of $302 million, up 11% and up 19% on a constant currency basis GAAP diluted EPS from continuing operations of $0.04, up 115% Non-GAAP diluted EPS of $0.56, up 6% Net cash provided by operating activities of $3